Across TCGA pan-cancer cohorts, JRKL mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated JRKL data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher JRKL mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated JRKL expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD and LSCC are the cancer types where JRKL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	1.000	0.894	.020	16	view →
LSCC	DFS	Median	All	0.468	1.000	.006	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: JRKL tumor-vs-normal RNA expression · all JRKL data types